Kestra Medical Technologies, Ltd. (KMTS) Research

Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.

Market snapshot

Symbol
KMTS
Price
$19.93
Day change
+4.45%
Market cap
$1.2B
P/E ratio
-7.27x
52-week range
13.25-30
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Next earnings
in 1 month
Analyst price target
$24.00

Peer companies

  • Azenta, Inc. (AZTA)
  • BioLife Solutions, Inc. (BLFS)
  • Evotec SE (EVO)
  • Neogen Corporation (NEOG)
  • NovoCure Limited (NVCR)
  • Precigen, Inc. (PGEN)
  • Pulse Biosciences, Inc. (PLSE)
  • STAAR Surgical Company (STAA)

Recent insider activity

  • Webster Brian Daniel — S-Sale (15000 shares) on 2026-06-15
  • Moran Timothy P. — A-Award (22704 shares) on 2026-06-03
  • Ford Alfred J Jr — A-Award (25227 shares) on 2026-06-03
  • Mahboob Vaseem — A-Award (25227 shares) on 2026-06-03
  • Umberger Traci S — A-Award (25227 shares) on 2026-06-03

Open Kestra Medical Technologies, Ltd. (KMTS) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.